Disease · MONDO_0020108
Comparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 11 of 11
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Fostamatinib vs Placebo: A Hemoglobin Response by Week 24 | 21 of 45 | 16 of 45 | 90 | NCT03764618 | Trial comparisons |
| Fostamatinib vs Placebo: Change From Baseline in Hemoglobin Level of 2 g/dL or Greater | 22 of 45 | 16 of 45 | 90 | NCT03764618 | Trial comparisons |
| Fostamatinib vs Placebo: Use of Rescue Antibody Autoimmune Hemolytic Anemia (AIHA) Regimens Use After Week 4 | 18 of 45 | 18 of 45 | 90 | NCT03764618 | Trial comparisons |
| Fostamatinib vs Placebo: Durable Hemoglobin Response | 16 of 45 | 12 of 45 | 90 | NCT03764618 | Trial comparisons |
| Fostamatinib vs Placebo: deaths from any cause | 2 of 45 | 3 of 45 | 90 | NCT03764618 | Trial comparisons |
| Fostamatinib vs Placebo: serious adverse events | 15 of 45 | 17 of 45 | 90 | NCT03764618 | Trial comparisons |
| Parsaclisib 1 mg QD vs Parsaclisib 2.5 mg QD: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 10 of 10 | 15 of 15 | 25 | NCT03538041 | Trial comparisons |
| Parsaclisib 1 mg QD vs Parsaclisib 2.5 mg QD: deaths from any cause | 0 of 10 | 1 of 15 | 25 | NCT03538041 | Trial comparisons |
| Parsaclisib 1 mg QD vs Parsaclisib 2.5 mg QD: serious adverse events | 6 of 10 | 5 of 15 | 25 | NCT03538041 | Trial comparisons |
| Parsaclisib vs Placebo: deaths from any cause | 0 of 11 | 0 of 6 | 17 | NCT05073458 | Trial comparisons |
| Parsaclisib vs Placebo: serious adverse events | 6 of 11 | 0 of 6 | 17 | NCT05073458 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0020108/comparisons